Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axcella Health Inc
(NQ:
AXLA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axcella Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
January 21, 2022
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...
Via
Benzinga
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
January 06, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Kickstarts Long COVID Phase 2 Clinical Trial
December 16, 2021
Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long...
Via
Benzinga
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
December 16, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
December 06, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
November 10, 2021
From
Axcella Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
November 08, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) ...
Via
Benzinga
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
November 02, 2021
From
Axcella Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 27, 2021
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Axcella To Test NASH Candidate In Long COVID Patients
October 26, 2021
Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last...
Via
Benzinga
64 Biggest Movers From Yesterday
October 28, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...
Via
Benzinga
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
October 26, 2021
From
Axcella Therapeutics
Via
Business Wire
60 Biggest Movers From Yesterday
October 27, 2021
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the...
Via
Benzinga
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
October 19, 2021
From
Axcella Therapeutics
Via
Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
Axcella Announces Upcoming Investor Conference Presentation
October 05, 2021
From
Axcella
Via
Business Wire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation
September 28, 2021
Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) to treat complex diseases, including liver...
Via
Benzinga
Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
September 24, 2021
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
September 22, 2021
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
September 22, 2021
Piper Sandler boosted the price target for Adobe Inc. (NASDAQ: ADBE) from $600 to $670. Adobe shares fell 3.5% to $623.50 in pre-market trading. Keybanc reduced the price target...
Via
Benzinga
Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials
September 09, 2021
Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a groundbreaking potential treatment for...
Via
Benzinga
Axcella Announces Upcoming Investor Conference Presentation
September 07, 2021
From
Axcella
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 01, 2021
Gainers INmune Bio (NASDAQ:INMB) shares ...
Via
Benzinga
Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market
August 30, 2021
Image Provided By Unsplash Liver diseases like cirrhosis and nonalcoholic steatohepatitis (NASH) are deadly and afflict millions of Americans with debilitating mental and physical...
Via
Benzinga
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
August 16, 2021
From
Axcella
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.